for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Fosun Pharmaceutical (Group)

600196.SS

Latest Trade

58.56CNY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

23.99

 - 

79.19

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
58.56
Open
--
Volume
--
3M AVG Volume
1,545.64
Today's High
--
Today's Low
--
52 Week High
79.19
52 Week Low
23.99
Shares Out (MIL)
2,562.90
Market Cap (MIL)
142,648.50
Forward P/E
47.92
Dividend (Yield %)
0.63

Next Event

Q2 2020 Shanghai Fosun Pharmaceutical Group Co Ltd Earnings Release

Latest Developments

More

Shanghai Fosun Pharmaceutical Says Received Approval For Clinical Trial Of Licensed Covid-19 Mrna Vaccine Product

Shanghai Fosun Pharmaceutical Group Says Unit Received Approval For Clinical Trial For Fcn-338 Tablet

Shanghai Fosun Pharmaceutical Group Says Unit Got Acceptance Notice For Licensed COVID-19 Vaccine Product Candidate BNT162b1

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.

Industry

Major Drugs

Contact Info

Building A, No. 1289 Yishan Road

SHANGHAI, SHA

200233

China

+86.21.33987870

http://www.fosunpharma.com

Executive Leadership

Qiyu Chen

Chairman of the Board, Executive Director

Fang Yao

Co-Chairman of the Board, Executive Director

Yifang Wu

President, Chief Executive Officer, Executive Director

Xiao Hui Guan

Chief Financial Officer, Senior Vice President

Yu Qing Chen

Senior Vice President

Key Stats

2.08 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

18.5K

2018

24.9K

2019

28.6K

2020(E)

32.5K
EPS (CNY)

2017

1.270

2018

1.070

2019

1.300

2020(E)

1.359
Price To Earnings (TTM)
49.44
Price To Sales (TTM)
5.14
Price To Book (MRQ)
4.86
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
70.75
LT Debt To Equity (MRQ)
43.32
Return on Investment (TTM)
6.78
Return on Equity (TTM)
4.71

Latest News

Latest News

BRIEF-Shanghai Fosun Pharmaceutical Group Says Fosun Pharmaceutical Industrial & BioNTech Entered License Deal

* BIONTECH GRANTED EXCLUSIVE LICENSE TO FOSUN PHARMACEUTICAL INDUSTRIAL TO DEVELOP VACCINE TARGETING COVID-19

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up